Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 583,500 shares, an increase of 20.0% from the November 30th total of 486,100 shares. Approximately 4.4% of the company’s stock are short sold. Based on an average daily volume of 174,600 shares, the short-interest ratio is currently 3.3 days.

Sensus Healthcare Trading Down 1.8 %

SRTS stock traded down $0.13 during trading hours on Friday, hitting $7.21. 318,480 shares of the stock traded hands, compared to its average volume of 273,869. The stock has a 50-day simple moving average of $7.61 and a 200 day simple moving average of $6.57. The company has a market cap of $118.16 million, a P/E ratio of 12.65 and a beta of 1.16. Sensus Healthcare has a one year low of $2.36 and a one year high of $9.33.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the business. Truvestments Capital LLC bought a new stake in shares of Sensus Healthcare in the 3rd quarter worth approximately $32,000. Geode Capital Management LLC increased its holdings in shares of Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after buying an additional 11,525 shares in the last quarter. Sachetta LLC lifted its position in shares of Sensus Healthcare by 12.9% during the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after acquiring an additional 13,544 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after acquiring an additional 13,619 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Sensus Healthcare during the 2nd quarter worth $156,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. HC Wainwright boosted their price objective on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, November 18th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.